Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

61. Choices of dose and formulation when dual therapies escalate into triple treatments for stable COPD patients: a meta-analysis of randomized controlled trials

Choices of dose and formulation when dual therapies escalate into triple treatments for stable COPD patients: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

62. Effective components of home-based pulmonary rehabilitation and follow-up strategies in COPD patients

Effective components of home-based pulmonary rehabilitation and follow-up strategies in COPD patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

63. Efficacy of low molecular weight heparin (LMWH) for chronic obstructive pulmonary disease (COPD) and respiratory failure (RF): a systematic review protocol of randomized controlled trials

Efficacy of low molecular weight heparin (LMWH) for chronic obstructive pulmonary disease (COPD) and respiratory failure (RF): a systematic review protocol of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

64. Sputum colour as a marker for the presence of bacteria in acute exacerbations of asthma and COPD

Sputum colour as a marker for the presence of bacteria in acute exacerbations of asthma and COPD Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

65. The efficacy of tiotropium bromide and formoterol (TBF) for the treatment of patients with chronic obstructive pulmonary disease (COPD): a systematic review protocol

The efficacy of tiotropium bromide and formoterol (TBF) for the treatment of patients with chronic obstructive pulmonary disease (COPD): a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

66. The association between fat free mass and health-related outcomes in people with COPD: a systematic review

The association between fat free mass and health-related outcomes in people with COPD: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

67. Revefenacin (Yupelri) - To treat patients with chronic obstructive pulmonary disease (COPD)

Revefenacin (Yupelri) - To treat patients with chronic obstructive pulmonary disease (COPD) Drug Approval Package: Yupelri (revefenacin) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Yupelri (revefenacin) Company: Theravance Biopharma Ireland Limited Application Number: 210598 Approval Date: 11/09/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling

2019 FDA - Drug Approval Package

68. Predictors of in-hospital mortality and mechanical ventilation in patients with acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD): systematic review and meta-analysis

Predictors of in-hospital mortality and mechanical ventilation in patients with acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD): systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

69. Traditional Chinese medicine for nutritional problem of stable COPD: a systematic review and meta-analysis

Traditional Chinese medicine for nutritional problem of stable COPD: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

70. Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis

Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

71. Investigational treatments in Phase I and II clinical trials in COPD patients: a systematic review

Investigational treatments in Phase I and II clinical trials in COPD patients: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

72. Pseudomonas in chronic obstructive pulmonary disease (COPD): a systematic review

Pseudomonas in chronic obstructive pulmonary disease (COPD): a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

73. Effects of telehealthcare on chronic obstructive pulmonary disease (COPD) patients with different disease severity and economic development levels: a systematic review and meta-analysis

Effects of telehealthcare on chronic obstructive pulmonary disease (COPD) patients with different disease severity and economic development levels: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

74. Comparison of end-of-life care in people with COPD or lung cancer: a systematic review

Comparison of end-of-life care in people with COPD or lung cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

75. Effect of pharmacist-led interventions on medication adherence and inhalation technique in patients with asthma or COPD: a systematic review and meta-analysis

Effect of pharmacist-led interventions on medication adherence and inhalation technique in patients with asthma or COPD: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

76. Distinguishing among pneumonic and non-pneumonic exacerbations in COPD: a systematic review and meta-analysis protocol

Distinguishing among pneumonic and non-pneumonic exacerbations in COPD: a systematic review and meta-analysis protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

77. COPD exacerbation: no systematic use of antibiotics

COPD exacerbation: no systematic use of antibiotics Prescrire IN ENGLISH - Spotlight ''COPD exacerbation: no systematic use of antibiotics'', 1 January 2019 {1} {1} {1} | | > > > COPD exacerbation: no systematic use of antibiotics Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight COPD exacerbation: no systematic use of antibiotics For episodes (...) of moderate aggravation in patients with chronic obstructive pulmonary disease (COPD), it is preferable to prescribe antibiotics as a first-line treatment only when the suspicion of bacterial infection is reinforced by an increase in sputum purulence. Patients with chronic obstructive pulmonary disease (COPD) are subject to exacerbations of their disease, i.e. episodes of prolonged aggravation. The known causes are mainly viral and bacterial infections. Some exacerbations justify hospitalisation: severe

2019 Prescrire

78. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis

Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis We performed a meta-analysis to compare the impact of triple combination therapy with inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs) and long-acting muscarinic receptor antagonists (LAMAs) versus LABA/LAMA combination therapy or single long-acting bronchodilator therapy in chronic obstructive pulmonary disease. The ICS/LABA/LAMA combination reduced the risk

2019 EvidenceUpdates

79. A randomised controlled trial to investigate the use of high-frequency airway oscillations as training to improve dyspnoea in COPD. (PubMed)

A randomised controlled trial to investigate the use of high-frequency airway oscillations as training to improve dyspnoea in COPD. Chronic obstructive pulmonary disease (COPD) is characterised by expiratory flow limitation resulting in symptomatic dyspnoea, sputum retention and ventilation heterogeneity. Changes in breathing mechanics affect the ability of respiratory muscles to respond to the ventilatory demands, increasing the sensation of dyspnoea. A high-frequency airway oscillating device (...) has been developed to combine respiratory muscle training and oscillations to improve dyspnoea and sputum retention within COPD.Patients with symptomatic COPD (Medical Research Council Breathlessness scale grade ≥2) will be recruited to a double-blind, randomised, sham-controlled trial. Both groups will follow an 8-week intervention phase using the device three times per day for 5 min at a time. This will be recorded in a self-reported diary. The device applies a flow resistive load

Full Text available with Trip Pro

2019 ERJ open research Controlled trial quality: predicted high

80. Efficacy and safety among LAMA / LABA in stable COPD patients: a systematic review and network meta-analysis

Efficacy and safety among LAMA / LABA in stable COPD patients: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO